<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Organ Transplant Med</journal-id><journal-id journal-id-type="iso-abbrev">Int J Organ Transplant Med</journal-id><journal-id journal-id-type="publisher-id">Ijotm</journal-id><journal-title-group><journal-title>International Journal of Organ Transplantation Medicine</journal-title></journal-title-group><issn pub-type="ppub">2008-6482</issn><issn pub-type="epub">2008-6490</issn><publisher><publisher-name>Avicenna Organ Transplantation Institute</publisher-name><publisher-loc>Shiraz, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28299023</article-id><article-id pub-id-type="pmc">5347401</article-id><article-id pub-id-type="publisher-id">ijotm-8-008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Osmotherapy and Tight Control of Acidosis on Early Graft Function among Deceased-Donor Kidney Transplant Recipients: A Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Etezadi</surname><given-names>F.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Najafi Abrandabadi</surname><given-names>A. H.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Motaharinia</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Mojtahedzadeh</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pourfakhr</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Khajavi</surname><given-names>M. R.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gooran</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Shariat Moharari</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dehghani</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Department of Anesthesiology and Critical Care, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran </italic></aff><aff id="aff2"><label>2</label><italic>Department of Pharmacotherapy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</italic></aff><aff id="aff3"><label>3</label><italic>Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran</italic></aff><author-notes><corresp id="cor1"><label>*</label>Correspondence: Dr. Javad Motaharinia, Department of Pharmacotherapy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran, Tel: +98-919-995-2505, Fax: +98-21-2204-8483, E-mail: motahariniaj@gmail.com</corresp></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="epub"><day>1</day><month>2</month><year>2017</year></pub-date><volume>8</volume><issue>1</issue><fpage>8</fpage><lpage>16</lpage><permissions><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Reperfusion injury and the acid-base status of the transplant are important factors affecting post-transplantation graft function.</p></sec><sec><title>Objective:</title><p>We hypothesized that infusing hypertonic saline (HS) or tight control of acid-base status of the blood rushing through renal graft using sodium bicarbonate may have beneficial effects on early graft function. </p></sec><sec><title>Methods:</title><p>Candidates for deceased-donor kidney transplant were randomized into three groups. HS group (n=33) received 50 mL/kg normal saline (NS) titrated during operation plus 4 mL/kg of 5% HS just within graft reperfusion phase; bicarbonate group (n=37) was administered 60 mL/kg NS while their metabolic acidosis (base excess &#x02264;5 mEq/L) was tightly corrected every 30 min with sodium bicarbonate; and a control group (n=36) that received 60 mL/kg normal saline while they were administered sodium bicarbonate only, if they encountered severe metabolic acidosis (base excess &#x02264;15 mEq/L). The primary outcome was defined as early post-operative renal function evaluated based on serial serum creatinine levels. The study was registered in Iranian Registry of Clinical Trials (IRCT2013122815841N19).</p></sec><sec><title>Results:</title><p>Post-operative early graft function improved significantly during the first 3 days in the intervention groups (p&#x0003c;0.05). However, that beneficial effect no longer remained at the same level after the day four. </p></sec><sec><title>Conclusion:</title><p>Timely administration of HS or tight control of metabolic acidosis with sodium bicarbonate infusion improve early renal function during renal transplant surgery.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Kidney transplantation</kwd><kwd>Deceased-donor</kwd><kwd>Acidosis</kwd><kwd>Bicarbonates</kwd><kwd>Saline solution</kwd><kwd>hypertonic</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Warm and cold ischemias are the two inevitable phenomena that affect deceased-donor kidney transplant. Although reperfusion is essential to stop ischemic injury, it may lead to further damage to the graft, a process the so-called &#x0201c;ischemia-reperfusion injury&#x0201d; (IRI) [<xref rid="B1" ref-type="bibr">1</xref>]. Infiltration of neutrophils, macrophages, and lymphocytes may play a major role in the damage [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>IRI may have a negative impact on kidney transplant outcome, which is one of the main causes of delayed graft function (DGF), especially in deceased-donor kidney transplantation [<xref rid="B3" ref-type="bibr">3</xref>]. In addition, kidney inflammation caused by IRI may lead to increased rate of acute graft rejection [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>Animal studies showed that an increase in plasma osmolality by infusing hypertonic saline (HS) can reduce the incidence of IRI [<xref rid="B5" ref-type="bibr">5</xref>-<xref rid="B8" ref-type="bibr">8</xref>]. In addition to having beneficial effects at the microcirculation level, infusion of HS has immune-modulator effects [<xref rid="B9" ref-type="bibr">9</xref>]. Infusion of HS, however, has some drawbacks such as hyperchloremic metabolic acidosis, hypernatremia, and fluid overload [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. Administration of chloride-enriched crystalloid solutions like normal saline (NS) and HS may aggravate the underlying acidosis in patients with end-stage renal disease [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Acidosis, apart from having adverse effects on hemodynamics, increases cytokine production and activates neutrophils [<xref rid="B13" ref-type="bibr">13</xref>]. Acidosis, itself, also has negative effects on renal function. For example, increased production of ammonia to adjust for the acid load in the body may cause interstitial kidney inflammation and damage [<xref rid="B14" ref-type="bibr">14</xref>]. Study on living donor kidney transplantation showed that intra-operative tight control of acidosis with administration of sodium bicarbonate improves early graft function [<xref rid="B15" ref-type="bibr">15</xref>]. However, experimental studies demonstrated that mild acidosis during early reperfusion reduces the incidence of IRI by preventing the activation of calpain enzymes and oxidative stress [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>We therefore hypothesized that timely administration of HS, which is a hyper-osmotic agent, as well as rational use of sodium bicarbonate, which is both hyper-osmotic and anti-acidosis agent, may enhance early graft function. We designed a randomized controlled trial to evaluate the effect of bolus administration of HS, administered within renal reperfusion, and tight correction of metabolic acidosis with sodium bicarbonate, administered before and during kidney reperfusion.</p></sec><sec sec-type="methods"><title>PATIENTS AND METHODS</title><p>
<bold>Patients</bold>
</p><p>All consecutive adult deceased-donor renal transplant recipients operated at transplant operating room of Sina Hospital between September 2013 and January 2015, were approached to participate in this randomized controlled trial. In the above-mentioned operating room, 10&#x02013;12 renal transplantations are done monthly and more than 1000 renal transplantations, including living and deceased-donor transplants, have been performed since 10 years ago. </p><p>The study was approved by the Ethics Committee of Tehran University of Medical Sciences. The study was registered in Iranian Registry of Clinical Trials (IRCT2013122815841N19). Inclusion criteria included first transplantation, deceased-donor kidney transplant, recipient age between 18 and 65 years, left ventricular ejection fraction of &#x0003e;30%, normal serum Na and K levels, panel reactive antibody of &#x0003c;20%, and donor serum creatinine of &#x0003c;2 mg/dL. Exclusion criteria included severe pre-operative or intra-operative acidosis (blood pH&#x02264;7.1 and/or serum bicarbonate level &#x02264;10 mEq/L and/or a base excess (BE) &#x02264;15 mEq/L), severe electrolyte abnormality ([K]&#x0003c;2.9 or &#x0003e;5.9 mEq/dL, or [Na]&#x0003c;125 or &#x0003e;145 mEq/dL), blood product transfusion, colloidal fluid administration, renal vein thrombosis, and graft anastomoses failure.</p><p>
<bold>Intervention</bold>
</p><p>All eligible patients were randomly assigned into three groups: 1) hypertonic saline, 2) sodium bicarbonate, and 3) control group. Permuted block randomization was used. Sample size calculation was based upon primary endpoints of early graft function and day three serum creatinine assuming a type one error of 0.05 and study power of 0.8 for detecting a 50% difference between studied groups, with a target of 22 patients in each group, given the standard deviations derived in our previous study [<xref rid="B15" ref-type="bibr">15</xref>].</p><p>Patients in the bicarbonate group were scheduled to receive 60 mL/kg of NS titrated during operation and also sodium bicarbonate 7.5% according to BE measurements. The acid-base status was measured just after induction of anesthesia and then, every 30 min up to the end of the operation. If the BE was &#x02264;5 mEq/L in every session, the sodium bicarbonate dose was calculated as follows:</p><p>[HCO<sub>3</sub>] (mEq) required = 0.3 &#x000d7; weight (kg) &#x000d7; BE (mEq/L)</p><p>Half of the dose was administered through the central venous catheter during 10 min. The patients were ventilated on continuous mandatory ventilation mode according to the initial setting of RR of 10, TV of 10 mL/kg, and I/E ratio of 1/2. The ventilator setting (RR or TV) was adjusted based on patient&#x02019;s PaCO<sub>2</sub> level to avoid bicarbonate-induced hypercarbia and keep the PaCO<sub>2</sub> between 35 and 40 mm Hg in all patients.</p><p>In the control group, about 60 mL/kg NS was titrated continuously during the operation via a central venous line to keep the central venous pressure between 10 and 15 cm H<sub>2</sub>O. In this group, in case of severe metabolic acidosis (BE &#x02264;15 mEq/L or pH&#x02264;7.1), the patient was excluded from the study and treated with sodium bicarbonate infusion calculated with the same formula and catecholamine infusion, if clinically indicated. </p><p>While 50 mL/kg of NS administered steadily to the patients in the HS group, they received 4 mL/kg HS 5% starting 10 min before graft reperfusion and lasting for about 15 min. We subtracted the amount of excess chloride given through HS infusion from that of the whole volume of NS, to avoid exacerbation of hyperchloremia in this group of patients. </p><p>Standard monitoring according to the recommendations of American Society of Anesthesiologists was used. Radial arterial cannula was inserted before the induction of anesthesia in order to monitor blood pressure as well as obtaining blood samples for arterial blood gas analysis. General anesthesia was induced with a combination of IV midazolam (0.05 mg/kg), fentanyl (2 &#x003bc;g/kg), and sodium thiopental (4 mg/kg). Anesthesia was maintained using isoflurane in an air/oxygen mixture and the bolus injection of fentanyl (2 &#x003bc;g/kg) every hour. IV injection of atracurium (0.2 mg/kg every 20 min) provided muscle relaxation.</p><p>The immunosuppressive regimen consisted of induction with daily anti-thymocyte globulin (ATG) at a dose of 1 mg/kg for 3&#x02013;7 days, followed by triple-drug immunosuppressive therapy. All patients received methylprednisolone 500 mg intra-operatively and then converted post-operatively to prednisone and tapered to 5 mg/day through several months. Mycophenolate mofetil was administered at a dose of 1000 mg twice daily, starting the day of transplantation. Cyclosporine (6 mg/kg/day twice daily) was administered after the serum creatinine level decreased to an acceptable level. All of the transplantation surgeries were performed by the same team consisted of two urologists and a vascular surgeon. </p><p>
<bold>Study Endpoints</bold>
</p><p>The primary outcome was to compare serum creatinine levels during the first three days after operation between study groups. As the secondary outcome, we categorized graft function to immediate graft function (IGF), slow graft function (SGF), and delayed graft function (DGF). DGF was defined by need for dialysis within the first week after transplantation. SGF was defined by the serum creatinine level &#x0003e;2.5 mg/dL on the fifth day of kidney transplantation. Those who showed a serum creatinine &#x0003c;2.5 mg/dL on the fifth day were categorized as IGF [<xref rid="B17" ref-type="bibr">17</xref>]. Other secondary end points were urine volume in the first week, and the incidence of acute rejection during the first month after transplantation. Acute rejection was diagnosed by a nephrology team through clinical and para-clinical investigations.</p><p>Serum creatinine was measured daily until discharge of the patient. Urine volume was recorded at 2, 6, and 24 hours after transplantation, then daily within the first week after transplantation. Recipient characteristics including age, sex, weight, body mass index, base-line acid-base status, base-line hemoglobin level, cause of end-stage renal disease, length of hemodialysis, time of the last hemodialysis session before transplantation, and donor characteristics including donor age, sex, serum creatinine, cause of brain death, and cold ischemia time, were recorded.</p><p>
<bold>Statistical Analysis</bold>
</p><p>Patient demographic information and baseline characteristics were summarized using descriptive statistics. Recipient, donor and transplant parameters were compared using <italic>Student&#x02019;s t</italic> test for independent samples or &#x003c7;<sup>2</sup> and Fisher&#x02019;s exact tests, when appropriate. If the continuous variables did not follow a normal distribution, Mann-Whitney U test was used. Different variants of multiple measurements were separately analyzed using repeated-measure analysis. Variables with a p&#x0003c;0.02 on univariate analysis were included in a binary logistic regression analysis to determine independent predictors of DGF. A p value &#x0003c;0.05 was considered statistically significant. Analyses were conducted with SPSS<sup>&#x000ae;</sup> for Windows<sup>&#x000ae;</sup> ver 17 (Chicago, IL, USA).</p></sec><sec sec-type="results"><title>RESULTS</title><p>From September 1, 2013 to January 31, 2015, a total of 129 potential deceased donor kidney transplant recipients was identified and screened for eligibility criteria. Nine patients were excluded with previous transplantation (n=4), donor serum creatinine &#x0003e;2 mg/dL (n=3), and age &#x0003e;65 years (n=2). The remaining 120 patients were randomized into three groups of HS, sodium bicarbonate, and control. The data of 37 patients in the sodium bicarbonate group, 33 in HS group, and 36 in the control group were included in the statistical analyses. <xref ref-type="fig" rid="F1">Figure 1</xref> presents the study flow chart. The baseline characteristics, intra-operative variables, and post-operative variables of recipient, donor, and transplant are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. </p><fig id="F1" position="float"><label>Figure 1</label><caption><p>CONSORT flow chart for the study</p></caption><graphic xlink:href="ijotm-8-008-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Recipient, donor, transplant characteristics, and intra-operative variables of the studied groups. Data are presented as mean (SD), n (%), or median [range</p></caption><table frame="hsides" rules="groups"><thead><tr><th style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Recipient Characteristics&#x02028;</th><th style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Control(n=36)</th><th style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Hypertonic Saline (n=33)</th><th style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Bicarbonate (n=37)</th><th style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Age (yrs)&#x02028;</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">46 (14)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">41 (10)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">42 (15)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.37</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Sex (%male)&#x02028;</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">60 </td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">72 </td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">48</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.1</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Weight (kg)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">70.8 (19.5)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">63 (10)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">63 (12)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.2</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Body mass index</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">24.7 (4)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">23.9 (4)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">25.2 (4.5)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.14</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Time on pre-transplant dialysis (month)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">15 [63]</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">24 [57]</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">9 [48]</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.3</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Last dialysis before transplant (day)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">1 [2]</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">1 [3]</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">1 [3]</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.7</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Pre-operation Hb (g/dL)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">9.5 (1.5)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">10.2 (0.9)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">9.9 (1.2)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.46</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Cause of end-stage renal disease (%)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1"/><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Diabetes</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">15</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">20</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">13</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="6" colspan="1">0.6</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Hypertension</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">33</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">20</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">39</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Obstructive uropathy</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">14</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">8</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">17</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Infection </td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">9.5</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">12.5</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Polycystic kidney</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">9.5</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Others</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">19</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">34.5</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">27</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" colspan="5" rowspan="1">Donor characteristics&#x02028;</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Age (yrs)&#x02028;</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">34(12)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">30 (12)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">34 (14)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.1</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Sex (%male)&#x02028;</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">76</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">64</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">62</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.4</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Serum creatinine (mg/dL) </td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">1.2 (0.35)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">1.26 (0.3)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">1.4 (0.3)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.57</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" colspan="5" rowspan="1">Cause of brain death (%)</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">CVA</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">30</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">8</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">18</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="5" colspan="1">0.12</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Head trauma</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">50</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">66</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">64</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Post-CPR </td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">10</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">18</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">9</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Drug intoxication</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">10</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4.5</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Brain tumor</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4.5</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" colspan="5" rowspan="1">Transplant characteristics&#x02028;</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Cold ischemic time (hr)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4.2 (1.1)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4.26 (1.1)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">4.09 (1.4)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.72</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">MAP at the time of graft reperfusion (mm Hg)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">103 (11)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">110 (10)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">110 (13)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.3</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" colspan="5" rowspan="1">Base-line acid-base status (after induction)</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Arterial pH </td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.34 (0.06)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.33 (0.07)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.33 (0.07)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.15</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Base excess (mEq/L)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.5 (3.7)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">6.8 (3.3)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.9 (3.8)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.08</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Serum bicarbonate (mEq/L)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">17 (4)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">18 (5)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">16 (7)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.7</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">PaCO<sub>2</sub> (mm Hg)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">37 (5)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">35(7)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">35(6)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" colspan="5" rowspan="1">Acid-base status 15 min after graft reperfusion</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Arterial pH </td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.25 (0.05)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.28 (0.01)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.33 (0.09)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.23</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Base excess (mEq/L)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">10.7 (3.2)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">7.8 (3.5)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">5.5 (4.0)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.037</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Serum bicarbonate (mEq/L)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">15 (5)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">16.9 (3)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">19.6 (4)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.7</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">PaCO<sub>2</sub> (mm Hg)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">36 (5)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">38 (3)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">37(7)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.39</td></tr><tr><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Saline 0.9% volume (mL/kg)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">57 (23)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">51 (19)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">59 (15)</td><td style="background-color:#FFFF00; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.65</td></tr><tr><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Chloride received during kidney transplantation (mEq/kg)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">8.9 (3.7)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">9.3 (4)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">9.1 (2.3)</td><td style="background-color:#F79646; color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.73</td></tr><tr><td style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">Incidence of acute rejection during first month (%)</td><td style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">35</td><td style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">24</td><td style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">21</td><td style=" color:#auto;" align="left" valign="middle" rowspan="1" colspan="1">0.1</td></tr></tbody></table><table-wrap-foot><p>CVA: Cerebrovascular accident; CPR: Cardiopulmonary resuscitation; MAP: Mean arterial pressure; ATG: Anti-thymocyte globulin; Hb: hemoglobin</p></table-wrap-foot></table-wrap><p>The overall incidence of DGF was 17%. The incidence of DGF did not significantly differ among the three groups, though. DGF in the control group was 28% (p=0.07; <xref ref-type="fig" rid="F2">Fig. 2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>The incidence of delayed, slow, and immediate graft function between sodium bicarbonate, HS, and control groups. The rate of DGF was lower in the sodium bicarbonate and HS groups but the difference is not significant (p=0.07). DGF was defined by need for dialysis within the first week after transplantation. SGF was defined by the serum creatinine level &#x0003e;2.5 mg/dL on the fifth day of kidney transplantation. The remaining graft function was considered IGF. Numbers in parenthesis indicate the number of patents.</p></caption><graphic xlink:href="ijotm-8-008-g002"/><p>HS: hypertonic saline; DGF: delayed graft function; SDF: slow graft function; IGF: immediate graft function</p></fig><p>Early post-transplantation graft function was significantly improved in patients who received sodium bicarbonate or HS solution, when mean serum creatinine levels were compared at post-operative day 1 to day 3 (p&#x0003c;0.05). Subsequent serum creatinine values continued to be lower for the sodium bicarbonate and HS group patients, but the difference was no longer significance at days 4&#x02013;7 (<xref ref-type="fig" rid="F3">Fig. 3-a</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Comparison of post-transplantation serum creatinine levels and urine volumes among three studied groups. a) patients treated with sodium bicarbonate or HS, the serum creatinine levels reached &#x0003c;2.5 mg/dL on the second and third day of kidney transplantation, respectively. Patients in the control group had serum creatinine level &#x0003c;2.5 mg/dL at day 6. b) Patients who received sodium bicarbonate or HS had significantly higher urine volume compared with control group at 2, 6, and 24 hours after transplantation.</p></caption><graphic xlink:href="ijotm-8-008-g003"/><p>HS: hypertonic saline. *p&#x0003c;0.05, **p&#x0003c;0.01, ***p&#x0003c;0.001</p></fig><p>Serum creatinine levels were not significantly different among studied groups at the hospital discharge. In patients who received sodium bicarbonate or HS, urine volume was significantly higher than that in the control group at 2, 6, and 24 hours after graft reperfusion (p&#x0003c;0.001). However, urine volume did not differ among the groups at the second day post-transplantation (<xref ref-type="fig" rid="F3">Fig. 3-b</xref>).</p><p>Multivariate analysis of data revealed that recipient sex, age, and weight, and donor age, cause of brain death, ATG induction, and base-line arterial blood gas parameters, were not independent predictors of DGF. The rate of acute graft rejection was less in bicarbonate group in comparison to other groups but the difference was not significant (p=0.07).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In the current study, we found that tight correction of acidosis with infusion of sodium bicarbonate or administration of HS just during graft reperfusion significantly improves early graft function up to the day three. Although the DGF rate was not significantly different between groups, considering the borderline p value obtained, this possibility should be kept in mind that if the study had been conducted in a larger sample size, we might have got a significant difference. The results of the current study supports the study conducted on living-donor transplant patients by Etezadi, <italic>et al</italic> [<xref rid="B15" ref-type="bibr">15</xref>]. </p><p>The overall incidence of DGF was 17%, while according to the figures released by the US Renal Data System in 2009, the rate of DGF in patients undergoing deceased-donor transplantation was from 20% to 40%. Cold ischemia time, which is one of the most important risk factors for DGF, is proved to increase the risk of DGF by 10% for every six hours [<xref rid="B18" ref-type="bibr">18</xref>]. In our center, the time interval between kidney harvest and transplant surgery was less than eight hours. Furthermore, in our study, the lower ages of kidney donors as well as the cause of their brain death, which was mostly accidents, were also two other contributors to reduce DGF rates. It was found that the rate of DGF increases with the donor&#x02019;s age; DGF rates for the ages of 20 and 65 years are 15% and 40%, respectively. According to United Network of Organ Sharing, DGF rate of the donors deceased by accidents is 18%; this rate is 30% for those who are involved in cerebrovascular events [<xref rid="B19" ref-type="bibr">19</xref>]. Body mass index (BMI) is regarded as a risk factor for DGF but our results did not support such a finding. </p><p>Evidence suggests that an increase of 10 to 20 osmole in plasma osmolality, caused by HS administration, may lead to the modulation of the immune system [<xref rid="B10" ref-type="bibr">10</xref>]. HS has the ability to reduce accumulation of immune cells and tissue damage compared to other crystalloid solutions [<xref rid="B20" ref-type="bibr">20</xref>]. In human studies, it has already been found that administration of 250 mL of HS is capable of enhancing plasma sodium and osmolality from 147 to 154 and 10 to 20 mOsm, respectively. However, the increase in osmolality is temporary and begins to decline after 30 to 60 min. It is in contrast to a study that revealed plasma osmolality remains high until six hours after administration of HS [<xref rid="B21" ref-type="bibr">21</xref>]. It is assumed that such a temporary increase in plasma osmolality is able to affect some functions of the immune system such as production of reactive oxygen species, release of metalloproteinases, and activation of endothelial cells, while the effect persists for up to 24 hours after HS administration [<xref rid="B22" ref-type="bibr">22</xref>]. </p><p>In a study conducted on a liver IRI model, HS administration just immediately before hepatic reperfusion could reduce tissue injury, while out of that time frame, it did not lead to the same beneficial effect [<xref rid="B23" ref-type="bibr">23</xref>]. Therefore, in our study, a HS bolus was administered immediately before the graft reperfusion in such a way that the middle of the administration coincided with the removal of renal artery clamp.</p><p>The disadvantage of chloride-rich crystalloid solutions is the induction of hyperchloremic acidosis caused by high chloride content and subsequent reduction of strong ion difference. Hyperchloremia may lead to afferent arteriole constriction, GFR reduction, and suppression of renin-angiotensin-aldosterone system which in turn, may lead to decreased urine production and sodium excretion [<xref rid="B24" ref-type="bibr">24</xref>]. Acidosis, itself, intensifies ammonia genesis process by the kidney. Enhanced production of ammonia leads to inflammation and kidney injury through activating alternative complement pathways [<xref rid="B14" ref-type="bibr">14</xref>]. Some studies have investigated the effects of different types of solutions, including NS, lactated ringer, and plasmalyte, on renal function [<xref rid="B25" ref-type="bibr">25</xref>-<xref rid="B28" ref-type="bibr">28</xref>]. However, no significant differences have been observed on renal function. Patients who received lactated ringer&#x02019;s solution had greater 4-hour urine volumes and 24-hour creatinine clearance than those who received NS [<xref rid="B27" ref-type="bibr">27</xref>]. In addition, metabolic acidosis due to hyper-chloremia in patients who were administered NS was more profound than in those who received lactated ringer&#x02019;s solution [<xref rid="B26" ref-type="bibr">26</xref>-<xref rid="B28" ref-type="bibr">28</xref>].</p><p>In the current literature, the effect of acidosis on the IRI is very controversial. Correction of acidosis may reduce IRI by modulating the immune system. On the one hand, growing evidence indicates that normal blood pH during tissue reperfusion causes exacerbation of oxidative stress, creation of mitochondrial permeability transition pore, increased apoptosis, and tissue damage [<xref rid="B29" ref-type="bibr">29</xref>]. Laboratory studies have demonstrated that the creation of transient acidosis (for three minutes) at the early stage of tissue reperfusion can reduce IRI. On the other hand, we know that acidosis may augment the release of NO and subsequently increases reactive oxygen species and apoptosis through PI3k-Akt-eNOS pathway [<xref rid="B30" ref-type="bibr">30</xref>]. Alternatively, post-ischemic conditioning has been proposed as a new strategy exerting short periods of acidosis for alleviating myocardial tissue and nervous damages caused by IRI [<xref rid="B16" ref-type="bibr">16</xref>]. It should be considered that the kidneys are the responsible organ for adjusting acid-base status in the body while the nervous and myocardial tissues lack such a duty. So, correction of acidosis in the blood rushed into a grafted kidney really means unloading an ischemic organ that is unable to function appropriately. It is why we got such a promising result with acidosis tight control strategy. An important concern is that we encountered five and two cases of severe metabolic acidosis in the HS and control groups, respectively. Those untoward events eventually led to the exclusion of the patients, while no patient in the bicarbonate group faced such an event. It should be noted that the only case of mortality in the bicarbonate group was due to a cardiovascular event on the fourth postoperative day. It seems that the patients in the bicarbonate group showed fewer serious complications during the study course than the other two groups.</p><p>One important finding, which needs more discussion, is that arterial blood pH and BE measured 15 min after renal reperfusion, were lower in NS-treated patients in comparison to other patients. This beneficial effect in bicarbonate group is understandable (osmotic diuresis and acidosis control due to bicarbonate therapy), but why a better acid-base status did occur in the HS group in comparison to the control group? We think it might be due to subsiding tubular cell tumescence and occurrence of earlier urinary flow and greater urine volume in these patients, which consequently led to a relative contraction alkalosis. </p><p>In conclusion, considering the significantly improved graft function until day three together with safer therapeutic course observed in the bicarbonate group, we suggest that although both tight control of acidosis and proper administration of HS were beneficial to early renal graft function, it seems that the bicarbonate therapy is the safest strategy. Larger and probably multicenter studies are needed to reveal delayed effects of these interventions.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>The authors would like to thank Sina Hospital Research Development Center for their technical assistance. This research has been supported by Tehran University of Medical Sciences and Health Services (grant NO: 23360).</p></ack><sec sec-type="COI-statement"><title>Conflicts of Interest:</title><p>None declared.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosieradzki</surname><given-names>M</given-names></name><name><surname>Rowinski</surname><given-names>W</given-names></name></person-group><article-title>Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention</article-title><source> Transplantation proceedings</source><year>2008</year><volume>40</volume><fpage>3279</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">19100373</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatauret</surname><given-names>N</given-names></name><name><surname>Badet</surname><given-names>L</given-names></name><name><surname>Barrou</surname><given-names>B</given-names></name><name><surname>Hauet</surname><given-names>T</given-names></name></person-group><article-title>Ischemia-reperfusion: From cell biology to acute kidney injury</article-title><source> Prog Urol</source><year>2014</year><volume>24 </volume><issue>Suppl 1</issue><fpage>S4</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">24950932</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menke</surname><given-names>J</given-names></name><name><surname>Sollinger</surname><given-names>D</given-names></name><name><surname>Schamberger</surname><given-names>B</given-names></name><etal/></person-group><article-title>The effect of ischemia/reperfusion on the kidney graft</article-title><source> Curr Opin Organ Transplant</source><year>2014</year><volume>19</volume><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">24905021</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikhalski</surname><given-names>D</given-names></name><name><surname>Wissing</surname><given-names>KM</given-names></name><name><surname>Ghisdal</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression</article-title><source> Transplantation</source><year>2008</year><volume>85</volume><fpage>S3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18401260</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name></person-group><article-title>Beneficial effects of hyperosmotic perfusion in the myocardium after ischemia/reperfusion injury in isolated rat hearts</article-title><source> Rev Bras Cir Cardiovasc</source><year>2013</year><volume>28</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">23739933</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LB</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Hypertonic perfusion reduced myocardial injury during subsequent ischemia and reperfusion in normal and hypertensive rats</article-title><source> Acta pharmacologica Sinica</source><year>2003</year><volume>24</volume><fpage>1077</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">14627488</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholz</surname><given-names>T</given-names></name><name><surname>Evans</surname><given-names>GR</given-names></name></person-group><article-title>Impact of hypertonic and hyperoncotic saline solutions on ischemia-reperfusion injury in free flaps</article-title><source> Plast reconstr surg</source><year>2008</year><volume>122</volume><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">18594390</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>CJ</given-names></name><name><surname>Winter</surname><given-names>DC</given-names></name><name><surname>Manning</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Hypertonic saline infusion for pulmonary injury due to ischemia-reperfusion</article-title><source> Arch surg</source><year>2003</year><volume>138</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12511143</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>JL</given-names></name><name><surname>Khwaja</surname><given-names>KA</given-names></name><name><surname>Chaudhury</surname><given-names>P</given-names></name><name><surname>Christou</surname><given-names>NV</given-names></name></person-group><article-title>Hypertonic saline and the microcirculation</article-title><source> J trauma</source><year>2003</year><volume>54</volume><fpage>S133</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12768115</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolsen-Petersen</surname><given-names>JA</given-names></name></person-group><article-title>Immune effect of hypertonic saline: fact or fiction?</article-title><source> Acta anaesthesiol Scand</source><year>2004</year><volume>48</volume><fpage>667</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">15196097</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JE</given-names></name><name><surname>Hall</surname><given-names>MJ</given-names></name></person-group><article-title>Hypertonic saline</article-title><source> J R Army Med Corps</source><year>2004</year><volume>150</volume><fpage>239</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">15732410</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnuelle</surname><given-names>P</given-names></name><name><surname>Johannes</surname><given-names>van der Woude F</given-names></name></person-group><article-title>Perioperative fluid management in renal transplantation: a narrative review of the literature</article-title><source> Transpl Int</source><year>2006</year><volume>19</volume><fpage>947</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">17081224</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Science review: extracellular acidosis and the immune response: clinical and physiologic implications</article-title><source> Critical care</source><year>2004</year><volume>8</volume><fpage>331</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15469594</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Abramowitz</surname><given-names>MK</given-names></name></person-group><article-title>Metabolic acidosis and the progression of chronic kidney disease</article-title><source> BMC nephrology</source><year>2014</year><volume>15</volume><fpage>55</fpage><pub-id pub-id-type="pmid">24708763</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etezadi</surname><given-names>F</given-names></name><name><surname>Pourfakhr</surname><given-names>P</given-names></name><name><surname>Mojtahedzade</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of tight versus non tight control of metabolic acidosis on early renal function after kidney transplantation</article-title><source> Daru</source><year>2012</year><volume>20</volume><fpage>36</fpage><comment>doi: 10.1186/2008-2231-20-36</comment><pub-id pub-id-type="pmid">23351673</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name></person-group><article-title>The protective effect of ischemic postconditioning against ischemic injury: from the heart to the brain</article-title><source> J Neuroimmune Pharmacol</source><year>2007</year><volume>2</volume><fpage>313</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18040849</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroppel</surname><given-names>B</given-names></name><name><surname>Legendre</surname><given-names>C</given-names></name></person-group><article-title>Delayed kidney graft function: from mechanism to translation</article-title><source> Kidney int</source><year>2014</year><volume>86</volume><fpage>251</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24522494</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ojo</surname><given-names>AO</given-names></name><name><surname>Wolfe</surname><given-names>RA</given-names></name><name><surname>Held</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Delayed graft function: risk factors and implications for renal allograft survival</article-title><source> Transplantation</source><year>1997</year><volume>63</volume><fpage>968</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">9112349</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cecka</surname><given-names>JM</given-names></name><name><surname>Terasaki</surname><given-names>PI</given-names></name></person-group><article-title>The UNOS scientific renal transplant registry United Network for Organ Sharing</article-title><source> Clin Transpl</source><volume>1995</volume><fpage>1</fpage><lpage>18</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Ruff</surname><given-names>P</given-names></name><etal/></person-group><article-title>Human neutrophil activation and increased adhesion by various resuscitation fluids</article-title><source> Crit care med</source><year>2000</year><volume>28</volume><fpage>74</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10667502</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizoli</surname><given-names>SB</given-names></name><name><surname>Rhind</surname><given-names>SG</given-names></name><name><surname>Shek</surname><given-names>PN</given-names></name><etal/></person-group><article-title>The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized, controlled, double-blinded trial</article-title><source> Ann surg</source><year>2006</year><volume>243</volume><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16371736</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junger</surname><given-names>WG</given-names></name><name><surname>Rhind</surname><given-names>SG</given-names></name><name><surname>Rizoli</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Resuscitation of traumatic hemorrhagic shock patients with hypertonic saline-without dextran-inhibits neutrophil and endothelial cell activation</article-title><source> Shock</source><year>2012</year><volume>38</volume><fpage>341</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">22777113</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueira</surname><given-names>ER</given-names></name><name><surname>Bacchella</surname><given-names>T</given-names></name><name><surname>Coelho</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Timing-dependent protection of hypertonic saline solution administration in experimental liver ischemia/reperfusion injury</article-title><source> Surgery</source><year>2010</year><volume>147</volume><fpage>415</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">20004454</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname><given-names>DN</given-names></name><name><surname>Awad</surname><given-names>S</given-names></name></person-group><article-title>Should chloride-rich crystalloids remain the mainstay of fluid resuscitation to prevent &#x02018;pre-renal&#x02019; acute kidney injury?</article-title><source> con Kidney Int</source><year>2014</year><volume>86</volume><fpage>1096</fpage><lpage>105</lpage><comment>doi: 10.1038/ki.2014.105</comment><pub-id pub-id-type="pmid">24717302</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadimioglu</surname><given-names>N</given-names></name><name><surname>Saadawy</surname><given-names>I</given-names></name><name><surname>Saglam</surname><given-names>T</given-names></name><etal/></person-group><article-title>The effect of different crystalloid solutions on acid-base balance and early kidney function after kidney transplantation</article-title><source> Anesth analg</source><year>2008</year><volume>107</volume><fpage>264</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18635497</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khajavi</surname><given-names>MR</given-names></name><name><surname>Etezadi</surname><given-names>F</given-names></name><name><surname>Moharari</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Effects of normal saline vs lactated ringer&#x02019;s during renal transplantation</article-title><source> Renal failure</source><year>2008</year><volume>30</volume><fpage>535</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18569935</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Huh</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Comparison of the effects of normal saline versus Plasmalyte on acid-base balance during living donor kidney transplantation using the Stewart and base excess methods</article-title><source> Transplant proc</source><year>2013</year><volume>45</volume><fpage>2191</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">23953528</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Malley</surname><given-names>CM</given-names></name><name><surname>Frumento</surname><given-names>RJ</given-names></name><name><surname>Hardy</surname><given-names>MA</given-names></name><etal/></person-group><article-title>A randomized, double-blind comparison of lactated Ringer&#x02019;s solution and 0.9% NaCl during renal transplantation</article-title><source> Anesth analg</source><year>2005</year><volume>100</volume><fpage>1518</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">15845718</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinten-Johansen</surname><given-names>J</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name><name><surname>Opie</surname><given-names>LH</given-names></name></person-group><article-title>Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction</article-title><source> Circulation</source><year>2005</year><volume>112</volume><fpage>2085</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16203924</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>QJ</given-names></name><etal/></person-group><article-title>Transient acidosis during early reperfusion attenuates myocardium ischemia reperfusion injury via PI3k-Akt-eNOS signaling pathway</article-title><source> Oxid Med Cell Longev</source><year>2013</year><volume>2013</volume><fpage>126083</fpage><pub-id pub-id-type="pmid">24312696</pub-id></element-citation></ref></ref-list></back></article>